ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "COVID-19"

  • Abstract Number: 1201 • ACR Convergence 2024

    Association of COVID-19 Vaccinations with Osteoarthritis Flares: A Case-Crossover Study

    Minerva Nong1, Colby Lewis V2, Genna Braverman3, Vivian Bykerk3, Nathaniel Hupert2, Medha Barbhaiya3 and Lisa Mandl3, 1Hospital for Special Surgery, Tampa, FL, 2Weill Cornell Medicine, New York, NY, 3Hospital for Special Surgery, New York, NY

    Background/Purpose: People with osteoarthritis (OA) commonly experience periods of increased pain and stiffness (“flares”), which can be distressing and disabling. Despite the prevalence of OA…
  • Abstract Number: 2182 • ACR Convergence 2024

    PECOS (Pediatric SARS-CoV-2 MIS-C Long-term Outcomes Study): Preliminary Results

    Gina Montealegre Sanchez1, Lauren Arrigoni2, Kevin Rubenstein3, Max Wolff4, Mallory Barrix2, C. Jason Liang5, James Bost6, Meghan Delaney7, Luigi Notarangelo8, Karyl Barron9 and Roberta DeBiasi10, and PECOS Study Team, 1Division of Clinical Research (DCR), National Institute of Allergy and Infectious Diseases (NIAID),National Institutes of Health (NIH), Bethesda, MD, 2Center for Cancer and Immunology Research (CCIR), Children's National Research Institute, Washington, DC, 3Clinical Monitoring Research Program Directorate (CMRPD), National Cancer Institute Frederick National Laboratory for Cancer Research, Frederick, MD, 4Clinical Research Directorate (CRD), National Cancer Institute Frederick National Laboratory for Cancer Research, Frederick, MD, 5Biostatistics Research Branch, NIAID, NIH, Bethesda, MD, 6Division of Biostatistics and Study Methodology and Center for Translational Research, Children's National Research Institute, Washington, DC, 7Department of Pathology and Laboratory Medicine, Children's National Hospital, Washington, DC, 8Laboratory of Clinical Immunology and Microbiology (LCIM), NIAID, Bethesda, MD, 9Division of Clinical Research (DCR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, 10Children's National Hospital and Research Institute, Washington, DC

    Background/Purpose: The long-term sequelae of SARS-CoV-2 infection in children are unknown. PECOS is a large prospective observational cohort study with the main objective to characterize…
  • Abstract Number: 0241 • ACR Convergence 2024

    Anti-Spike Antibodies in SARS-CoV-2-Vaccinated SLE Patients

    Rebecca Sadun1, Dan Crair1, Emmanuel Walter1, Eugene St.Clair2, David Pisetsky2, Amanda Eudy3, Megan Clowse4, Jennifer Rogers5, Kai Sun1, Lisa Criscione-Schreiber6, Mithu Maheswaranathan6, Jayanth Doss1, Sarah Valencia1 and M. Athony Moody7, 1Duke University, Durham, NC, 2Duke University Medical Center, Durham, NC, 3Duke University, Raleigh, NC, 4Duke University, Chapel Hill, NC, 5Duke, Durham, NC, 6Duke University School of Medicine, Durham, NC, 7Duke University School of Medicine, Durham

    Background/Purpose: The ACR recommends SARS-CoV-2 vaccination for all patients with rheumatic diseases, but it is unknown how patients with SLE will respond to the vaccine,…
  • Abstract Number: 1249 • ACR Convergence 2024

    Patient-Reported Outcomes in Inflammatory Arthritis: A Four-Year Retrospective Analysis via the PatientSpot Research Registry

    Shilpa Venkatachalam1, Kelly Gavigan2, Erik Stone3, Angela Degrassi2, Laura Stradford4, David Curtis2, Esteban Rivera5 and Jeffrey Curtis6, 1Global Healthy Living Foundation, New York, NY, 2Global Healthy Living Foundation, Upper Nyack, NY, 3Global Healthy Living Foundation, Upper Nyack, 4Global Healthy Living Foundation, Nyack, NY, 5Global Healthy Living Foundation, Long Island City, NY, 6University of Alabama at Birmingham, Hoover, AL

    Background/Purpose: Understanding the impact of inflammatory arthritis from patients’ perspectives through patient-reported outcomes (PROs) data can provide valuable insights into outcomes prioritized by those living…
  • Abstract Number: 2198 • ACR Convergence 2024

    Severe and Long-Term Outcomes of COVID-19 Infection and Vaccine Hesitancy and Adverse Events in Children with Pediatric Rheumatic Diseases: Insights from a COVID-19 Global Rheumatology Alliance Caregiver Survey

    Jonathan Hausmann1, Kevin Kennedy2, Ethan Knapp3, Nadine Lalonde4, jOhn Wallace5, Richard Howard6, Marcela Alvarez7, Mariana Fabi8, Lorena Franco9, Rebecca Grainger10, Jean Liew11, Pedro M Machado12, Zachary Wallace13, Jinoos Yazdany14 and Emily Sirotich15, and COVID-19 Global Rheumatology Alliance, 1Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, 2McMaster University, Hamilton, ON, Canada, 3University of Connecticut School of Medicine, Farmington, CT, 4COVID-19 Global Rheumatology Alliance, London, ON, Canada, 5Covid 19 Global Rheumatology Alliance Patient Board, EDINBURGH, United Kingdom, 6Spondylitis Association of America, Encino, CA, 7CHIDRENS HOSPITAL DR. RICARDO GUTIERREZ ARGENTINA, Buenos Aires, Argentina, 8Argentine Society of Rheumatology, La Plata, Argentina, 9Argentine Society of Rheumatology, Cordoba, Argentina, 10University of Otago, Wellington, New Zealand, 11Boston University, Boston, MA, 12Department of Neuromuscular Diseases and Centre for Rheumatology, University College London, London, United Kingdom, 13Massachusetts General Hospital, Newton, MA, 14UCSF, San Francisco, CA, 15Yale University, Vaughan, ON, Canada

    Background/Purpose: Children have the lowest COVID-19 vaccination rates of any age group. In adults with rheumatic diseases, barriers to vaccination include the perceived lack of…
  • Abstract Number: 0152 • ACR Convergence 2023

    Long Covid in Persons with Self-Reported Arthritis – Symptoms, Associated Factors and Functional Limitations

    Debbie Ehrmann Feldman1 and Barbara Mazer2, 1Université de Montréal, Montreal, QC, Canada, 2McGill University, Montreal, QC, Canada

    Background/Purpose: Long covid, a condition whereby signs and symptoms post covid-19 infection continue for more than 12 weeks and are not explained by an alternative…
  • Abstract Number: 0223 • ACR Convergence 2023

    Severity and Risk Factors of Hospitalization of Omicron in Patients with Rheumatoid Arthritis

    Yan Wang1, mengyao zhang2, Sitian Zang1, liang luo3, Chun Li1, Jing He1 and zhanguo li2, 1Peking University People’s Hospital, Beijing, China, 2Peking University People's Hospital, Beijing, China, 3Department of Chinese Medicine, the People's Hospital of Yubei District of Chongqing City, Chongqing, China; Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China

    Background/Purpose: There is still lack of data on the prognosis of patients with RA who have been infected with SARS-Cov-2 Omicron variant, a new strain…
  • Abstract Number: 1093 • ACR Convergence 2023

    Development of Adaptive Immunity Against Different SARS-CoV-2 Variants over the Course of Three COVID-19 Vaccinations in Patients with Inflammatory Rheumatic Diseases

    Liam Huppke1, Paul Wratil2, Marie Bischof2, Stefan Wolfrum1, Fabian Ullrich1, Delila Singh1, Julia Lichtnekert1, Lea Grümme1, Christina Gebhardt1, Klaus Krüger3, Franziska Wiesent4, Alla Skapenko1, Oliver Keppler5 and Hendrik Schulze-Koops6, 1Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, 2Max von Pettenkofer Institute & Gene Centre, Virology, National Reference Centre for Retroviruses, LMU Munich, Munich, Germany, 3Praxiszentrum St. Bonifatius, Munich, Germany, 4Endokrinologikum München, Munich, Germany, 5Max von Pettenkofer Institute & Gene Centre, Virology, National Reference Centre for Retroviruses, LMU München, Munich, Germany, 6Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, Ludwig-Maximilians–University Munich, Munich, Germany

    Background/Purpose: Even though individuals with inflammatory rheumatic diseases (IRDs) were excluded from the SARS-CoV-2 vaccine trails, studies have shown that these individuals at risk of…
  • Abstract Number: 1677 • ACR Convergence 2023

    Two-week Break in Methotrexate Treatment and COVID-19 Vaccine Response. Results of the Vaccine Response on off Methotrexate (VROOM) Study, an Open Label, Prospective, Two-arm Parallel-group, Multi-center, Superiority, Randomized Controlled Trial

    Abhishek Abhishek1, Nicholas Peckham2, Corinna Pade3, Joseph Gibbons3, Lucy Cureton2, Anne Francis2, Vicki Barber2, Jennifer Williams2, duncan Appelbe2, lucy Eldridge2, patrick Julier2, daniel Altmann4, James Bluett5, Tim Brooks6, Laura Coates2, ines Rombach7, Amanda Semper6, Ashley Otter6, Ana Valdes1, Jonathan Nguyen-Van-Tam1, Hywel Williams1, Aine McKnight3, Rosemary Boyton4 and jonathan Cook2, 1University of Nottingham, Nottingham, United Kingdom, 2University of Oxford, Oxford, United Kingdom, 3Queen Mary University of London, London, United Kingdom, 4Imperial College London, London, United Kingdom, 5University of Manchester, Manchester, United Kingdom, 6UK Health Security Agency, Porton Down, United Kingdom, 7University of Sheffield, Sheffield, United Kingdom

    Background/Purpose: Immunosuppressive treatments inhibit vaccine-induced immunity. We evaluated if a two-week interruption of methotrexate treatment immediately after COVID-19 booster improved antibody response against spike protein…
  • Abstract Number: 1935 • ACR Convergence 2023

    Pre-exposure Prophylaxis with Tixegvimab/cilgavimab Is Effective in Limiting the Risk and Severity of COVID-19 in Patients with Auto Immune or Inflammatory Diseases at Increased Risk of Severe COVID-19

    Marion THOMAS1, Maeva MASSON2, Raphaele Seror3, Samuel Bitoun4, Henry DUPUY5, Lazato ESTIBALIZ5, Christophe Richez6, Yannick ALLANORE7 and Jerome AVOUAC8, 1HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, 2CHU Toulouse, Toulouse, France, 3University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, 4CHU Bicêtre APHP, Le Kremlin-Bicêtre, France, 5CHU Bordeaux, Bordeaux, France, 6Université de Bordeaux, Bordeaux, France, 7Université Paris Cité, Paris, France, 8Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France

    Background/Purpose: Patients with autoimmune or inflammatory diseases treated with immunosuppressants such as anti-CD20 are at increased risk for severe COVID-19 and have a high probability…
  • Abstract Number: 2536 • ACR Convergence 2023

    DMARD Adherence During the COVID-19 Pandemic and Association with Risk of COVID-19 Infection

    Tanya Selvam, Kelli Peterman, Arezoo Haghshenas and Lucy Liu, Kaiser Permanente Northern California, Oakland, CA

    Background/Purpose: The COVID-19 pandemic affected medication adherence in patients with autoimmune disease (AD) due to their fear of contracting COVID-19, financial hardship, and medication shortage.…
  • Abstract Number: 0202 • ACR Convergence 2023

    Analysis of the Effects of Immunosuppressive Therapy on Herpes Zoster Events After Each of Three Doses of the BNT162b2 mRNA Vaccine in Patients with Spondyloarthritis (SpA)

    Tal Gazitt1, Noa Hayat2, Amir Haddad2, Joy Feld3, Nili Stein2, Idit Lavi2, Ilan Feldhamer4, Arnon Dov Cohen5, Walid Saliba2 and Devy Zisman2, 1Carmel Hospital, Haifa, Israel, 2Carmel Medical Center, Haifa, Israel, 3Carmel and Zvulun Medical Centre, Haifa, Israel, 4Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel, 5Ben-Gurion University of the Negev, Beer-Sheva, Israel

    Background/Purpose: The importance and efficacy of mRNA COVID-19 vaccination in coping with the pandemic are well established, but inconsistencies remain in the data regarding side…
  • Abstract Number: 0224 • ACR Convergence 2023

    Risk Factors and Outcomes for Repeat COVID-19 Infection Among Patients with Systemic Autoimmune Rheumatic Diseases: A Case-control Study

    Emily Kowalski1, Xiaosong Wang1, Naomi Patel2, Yumeko Kawano1, Claire Cook2, Kathleen Vanni1, Grace Qian1, Katarina Bade3, Shruthi Srivatsan2, Zachary Williams2, Zachary Wallace4 and Jeffrey Sparks5, 1Brigham and Women's Hospital, Boston, MA, 2Massachusetts General Hospital, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4Massachusetts General Hospital, Newton, MA, 5Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: As initial COVID-19 infections become nearly ubiquitous and the available prevention and treatment strategies evolve, patients with systemic autoimmune rheumatic diseases (SARDs) may be…
  • Abstract Number: 1141 • ACR Convergence 2023

    COVID-19 Vaccination Status and Adverse Events Following SARS-CoV-2 Vaccine in Autoimmune Inflammatory Rheumatic Disease (AIRD) Patients: A Single Center Experience

    Vincent Luceño1, Peter Paolo Daleon1 and Sandra Navarra2, 1University of Santo Tomas Hospital, City of Manila, Philippines, 2University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines

    Background/Purpose: Autoimmune inflammatory rheumatic diseases (AIRD) were associated with an increased risk for COVID-19 infection, worse clinical outcomes, and COVID-19- related deaths. Vaccines carry the…
  • Abstract Number: 1754 • ACR Convergence 2023

    Novel and Unique Rheumatoid Factors Cross-React with Viral Epitopes in COVID-19

    Maya Amjadi1, Maxwell Parker2, Zihao Zheng1, Alex Robbins1, Michael Denny1, Sara McCoy3, Irene Ong1 and Miriam Shelef1, 1University of Wisconsin, Madison, WI, 2University of Wisconsin-Madison, Madison, WI, 3University of Wisconsin School of Medicine and Public Health, Middleton, WI

    Background/Purpose: Rheumatoid factors (RFs), polyreactive antibodies canonically known to bind two conformational epitopes of IgG, are a hallmark of rheumatoid arthritis but also can arise…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 38
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology